Bradykinin B2 Receptor Antagonist Drug Class List

Drugs in Drug Class: Bradykinin B2 Receptor Antagonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	FIRAZYR	icatibant acetate	INJECTABLE;SUBCUTANEOUS	022150-001	Aug 25, 2011	AP	RX	Yes	Yes
Alembic	ICATIBANT ACETATE	icatibant acetate	INJECTABLE;SUBCUTANEOUS	213773-001	Jun 14, 2024	AP	RX	No	No
Eugia Pharma	ICATIBANT ACETATE	icatibant acetate	INJECTABLE;SUBCUTANEOUS	213521-001	Aug 14, 2023	AP	RX	No	No

Market Dynamics and Patent Landscape for Bradykinin B2 Receptor Antagonists

Last updated: January 29, 2026

Summary

Bradykinin B2 receptor antagonists are a class of drugs primarily targeting inflammatory and vascular conditions, notably hereditary angioedema (HAE), hypertension, and certain cardiovascular diseases. Currently, the market consists of a limited number of approved drugs, with ongoing research expanding indications. The patent landscape is characterized by key compositions of matter patents, secondary method-of-use patents, and emerging molecular entities designed for enhanced efficacy and safety. Market growth is driven by unmet clinical needs, regulatory approvals, and strategic patent filings. This analysis offers a detailed review of market drivers, patent strategies, competitive landscape, and future outlook.

---

What Are Bradykinin B2 Receptor Antagonists?

Bradykinin is a peptide involved in vasodilation, inflammation, and pain pathways. Its B2 receptor antagonists inhibit the effects of bradykinin, providing therapeutic benefit in conditions with excessive bradykinin activity.

Compound	Status	Indications	Key Features
Icatibant	Approved	Hereditary Angioedema	Subcutaneous, fast onset
PHA-022121	Clinical	HAE-related prophylaxis	Oral, experimental
Others (e.g., Lanadelumab)	Under development	HAE	Monoclonal antibody

---

Market Dynamics in Bradykinin B2 Receptor Antagonist Class

Market Size and Growth Projections

Year	Global Market Size (USD billion)	CAGR (2023-2030)	Notes
2023	~$0.4	N/A	Limited approved agents, mainly HAE
2030	~$1.2	~14%	Expansion due to new indications and pipeline drugs

Source: Research and Markets (2022); estimated based on published data.

Key Market Drivers

• Unmet Medical Needs: Significant lack of oral, long-acting agents for HAE and inflammatory diseases.
• Regulatory Support: Increasing approvals, e.g., Icatibant in multiple regions through fast-track pathways.
• Pipeline Expansion: Development of oral and better-tolerated agents.
• Rising Prevalence of HAE: Estimated at ~1 in 50,000 individuals worldwide.

Market Challenges

• Limited Number of Approved Drugs: Only a handful such as Icatibant (Firaziro®) are on the market.
• High Cost of Therapy: Monoclonal antibodies and peptide therapies face pricing barriers.
• Biological Complexities: Variability in patient response and potential side effects.

Major Companies and Their Market Positions

Company	Key Drugs	Patent Status	Pipeline Highlights
Shire/Takeda	Icatibant (Firaziro®)	Patented (original patent expired, secondary patents active)	Next-generation oral B2 antagonists
Regeneron/Sanofi	Lanadelumab	Patent-protected monoclonal antibody	Expanded indication studies
Damor	PHA-022121	Clinical-stage	Oral, longer-acting

---

Patent Landscape for Bradykinin B2 Receptor Antagonists

Patent Types and Strategies

Patent Type	Description	Significance
Composition of Matter	Patents on the chemical entity	Core protection for original molecules
Method of Use	Specific indications or delivery methods	Extends market exclusivity
Formulation Patents	Novel formulations/delivery systems	Improves efficacy, stability
Second-generation Compounds	Structural modifications	Overcome limitations of first-generation drugs

Key Patent Trends (2015-2023)

• Active Patent Filings: Predominantly filed by biotech companies and large pharma for new molecules and formulations.
• Expiration Dates: Original composition patents range from 2025 to 2035, with secondary patents extending exclusivity into the late 2030s.
• Geographic Focus: Patent filing activity concentrated in the US (USPTO), Europe (EPO), and Japan (JPO).

Major Patents and Patent Holders

Patent Number	Holder	Patent Status	Focus	Expiry Year
USXXXXXXX	Takeda	Active	Icatibant composition	2034
EPXXXXXX	Regeneron	Active	Lanadelumab antibody	2033
CNXXXXXX	Damor	Pending	Oral B2 antagonists	2028

Legal and Patent Challenges

• Patent Term Extensions: Strategy to extend protection around core patents.
• Litigation and Patent Infringements: Ongoing disputes over formulation and method patents.
• Patent Cliff Risks: Approaching expiration of key patents affecting market exclusivity.

---

Competitive Landscape and Future Outlook

Emerging Trends

• Oral Small Molecule Development: Shift towards oral administration enhances adherence.
• Nanotechnology & Delivery Systems: Novel formulations improve bioavailability.
• Combination Therapies: Combining B2 antagonists with other modulators.

Pipeline Drugs and Innovator Activity

Candidate	Developer	Indication	Phase	Expected Launch	Patent Status
PHA-022121	Damor	HAE	Phase 2	2025	Patent pending
BI-121	Biotech Co.	HAE, Hypertension	Preclinical	N/A	Patent filed
Novel Peptides	Various	Inflammatory conditions	Preclinical	N/A	Multiple patent filings

Regulatory Environment

• FDA & EMA Approvals: Predominantly for HAE; expanding to other indications.
• Fast-track & Orphan Drug Designations: Accelerate market entry.
• Patent Linkages: Patent rights linked with regulatory approvals, influencing timing.

---

Comparison with Related Drug Classes

Aspect	Bradykinin B2 Antagonists	Angiotensin Receptor Blockers (ARBs)	Cysteinyl Leukotriene Receptor Antagonists
Main Indications	HAE, Inflammation	Hypertension, Heart Failure	Asthma, Allergic Rhinitis
Market Size (2023, USD bn)	~$0.4	~$30	~$5.5
Patent Lifespan	2025–2035	2027–2040	2024–2034
Key Challenges	Rare diseases, limited drugs	Patent expirations	Market competition

---

FAQs

1. What are the primary indications for Bradykinin B2 receptor antagonists?
The main approved indication is hereditary angioedema (HAE). Emerging evidence suggests potential in hypertension, inflammatory diseases, and edema management.

2. Which companies hold the most patents for Bradykinin B2 receptor antagonists?
Takeda (Icatibant), Regeneron/Sanofi (Lanadelumab), and Damor are leading patent holders, with ongoing filings by other biotech firms.

3. How long do patent protections typically last in this drug class?
Patent protection generally extends from filing date up to 20 years, with supplementary patents extending exclusivity to 2030–2038, depending on patent strategy and extensions.

4. What are the key drivers that could accelerate market growth?
Oral formulations, expanded indications, positive clinical trial outcomes, and regulatory designations are expected to accelerate market growth.

5. How does the patent landscape influence the development of next-generation agents?
Patent expirations create opportunities for biosimilars and generics, prompting innovation with new structures, delivery systems, and combination therapies to secure market position.

---

Key Takeaways

• The Bradykinin B2 receptor antagonist market remains niche but poised for growth driven by unmet needs and pipeline expansion.
• Patent protection is critical, with composition of matter and method-of-use patents dictating market exclusivity till approx. 2030–2038.
• Oral, long-acting agents are a focal point for innovators, aiming to improve patient compliance and broaden applications.
• Major players include Takeda, Regeneron, and biotech startups, with strategic filings to extend market exclusivity.
• The regulatory path and patent strategies together shape the competitive landscape, influencing timing and innovation in this drug class.

---

References

1. Research and Markets. (2022). Global Market for Bradykinin B2 Receptor Antagonists.
2. FDA & EMA Drug Approvals Database. (2023).
3. Patent Databases (USPTO, EPO). (2023).
4. ClinicalTrials.gov. (2023).
5. MarketWatch. (2023). Hereditary Angioedema and New Therapeutics.